Registering a pharmaceutical trademark is not a single-step process. Before a product name can reach the market, it must pass two separate assessments. In fact, up to 65% of pharmaceutical brand names fail one of these two reviews.
In the pharmaceutical sector, securing trademark protection is only part of the challenge. A proposed brand name must not only be registrable before an intellectual property office, but also be approved by health authorities, which assess whether the name could lead to medication errors, cause confusion in a clinical setting, or resemble the names of existing medicinal products or active substances.
The consequences of an ineffective pharmaceutical naming strategy can be significant. According to our estimates, trademark applications for pharmaceutical brand names that ultimately fail approval generate more than €200 million in annual losses worldwide. In addition, every day of delay in bringing a new medicine to market results in an average of US$800,000 in lost sales. In therapeutic areas such as cardiovascular disease, immunology and haematology, losses can approach US$2 million per day.
At ClarkeModet, we have developed a practical guide to help pharmaceutical and biotechnology companies successfully navigate this dual review process across Europe and Latin America, reducing the risk of objections, rebranding, repeated filings and launch delays.
The guide provides an integrated perspective based on our experience supporting thousands of pharmaceutical and biotech companies in the development of pharmaceutical naming strategies, trademark clearance programmes and regulatory roadmaps tailored to the specific requirements of each market.
Download the guide and learn how to improve approval rates for pharmaceutical brand names while accelerating market access.